中国临床实用医学
中國臨床實用醫學
중국림상실용의학
CHINA CLINICAL PRACTICAL MEDICINE
2008年
12期
37-39
,共3页
非小细胞肺癌%放疗%化疗%同步放化疗
非小細胞肺癌%放療%化療%同步放化療
비소세포폐암%방료%화료%동보방화료
Non small cell lung cancer%Radiotherapy%Chemotherapy%Concurrent chemo-radiotherapy
目的 用PE方案比较同步放化疗与序贯化放疗治疗Ⅲ期不能手术非小细胞肺癌的近期疗效和毒性反应.方法 资料完整共计62例患者纳人统计分析.两组患者均用PE方案化疗,顺铂40mg、足叶乙甙200 mg第1～3天,每3～4周重复.同步组在放疗第1天开始化疗,序贯组先化疗2个周期后再放疗.放射治疗肿瘤剂量60～63 Gy/6～7周.结果 同步组与序贯组近期有效率分别是77.4%和63.3%无显著性差别(x2=0.93,P=0.818),1、2、3年生存率分别为59.4%、40.1%、28.1%和53.3%、33.3%、20.1%,中位生存时间分别为19.2个月和12.7个月有显著性差别(x2=4.588,P=0.032).常见毒性反应是白细胞减少、恶心、呕吐、放射性食管炎及放射性肺炎,两组发生率相近,差别无显著性.结论 同步放化疗对Ⅲ期不能手术的非小细胞肺癌治疗有益,毒性反应发生率有所增加,可耐受.
目的 用PE方案比較同步放化療與序貫化放療治療Ⅲ期不能手術非小細胞肺癌的近期療效和毒性反應.方法 資料完整共計62例患者納人統計分析.兩組患者均用PE方案化療,順鉑40mg、足葉乙甙200 mg第1～3天,每3～4週重複.同步組在放療第1天開始化療,序貫組先化療2箇週期後再放療.放射治療腫瘤劑量60～63 Gy/6～7週.結果 同步組與序貫組近期有效率分彆是77.4%和63.3%無顯著性差彆(x2=0.93,P=0.818),1、2、3年生存率分彆為59.4%、40.1%、28.1%和53.3%、33.3%、20.1%,中位生存時間分彆為19.2箇月和12.7箇月有顯著性差彆(x2=4.588,P=0.032).常見毒性反應是白細胞減少、噁心、嘔吐、放射性食管炎及放射性肺炎,兩組髮生率相近,差彆無顯著性.結論 同步放化療對Ⅲ期不能手術的非小細胞肺癌治療有益,毒性反應髮生率有所增加,可耐受.
목적 용PE방안비교동보방화료여서관화방료치료Ⅲ기불능수술비소세포폐암적근기료효화독성반응.방법 자료완정공계62례환자납인통계분석.량조환자균용PE방안화료,순박40mg、족협을대200 mg제1～3천,매3～4주중복.동보조재방료제1천개시화료,서관조선화료2개주기후재방료.방사치료종류제량60～63 Gy/6～7주.결과 동보조여서관조근기유효솔분별시77.4%화63.3%무현저성차별(x2=0.93,P=0.818),1、2、3년생존솔분별위59.4%、40.1%、28.1%화53.3%、33.3%、20.1%,중위생존시간분별위19.2개월화12.7개월유현저성차별(x2=4.588,P=0.032).상견독성반응시백세포감소、악심、구토、방사성식관염급방사성폐염,량조발생솔상근,차별무현저성.결론 동보방화료대Ⅲ기불능수술적비소세포폐암치료유익,독성반응발생솔유소증가,가내수.
Objective Use PE regimen to evaluate the short-term curative effect and toxicity effects of concurrent chemo-radiotherapy (CCRT) and sequential chemo-radiotherapy (SCRT) for unresectable Stage Ⅲ non-small cell lung eaneer. Methods 62 patients with complete record were involved in the statistical analysis. The patients were randomized into 2 groups, which were both treated by chemotherapy with PE regimen, with cis-platin 40 mg/m2 on DI-3 and 200 mg/m2 ,etoposide on D1-3,repeated every 3-4 weeks. CCRT group received chemotherapy after the first day of radiotherapy; SCRY group received radiotherapy after two cycles of chemo-therapy. Radiotherapy was given to a total dose of 60 Gy-63 Gy/6-7 weeks. Results The overall response rates of CCRT group and SCRY group were 77.4% and 63.3% respectively ,and the differences were not significant in terms of immediate response(x2 =0.93 ,P =0.818). The 1-,2-aad 3-year survival rates were 59.4% ,40.1%, 28.1%and 53.3% ,33.3% ,20.1%in CCRT and SCRT groups; The median survival periods were 19.2 months and 12.7 months respectively,and the difference in the survival rates were quite significant (x2 = 4.588, P =0.032). The common treatment-related toxieities were leukopenia, nausea and vomiting, radiation esophagitis, and pneumonitis; the incidence was similar in both groups, and there were no differences in terms of treatment-related toxicities. Conclusion CCRT is one of the beneficial approaches for the treatment of patients with unre-sectable stage Ⅲ non-small cell lung cancer;the incidence of toxieities increases slightly, however,it is well tol-erated.
